Clinical trials · Pittsburgh, PA
Neoplasms clinical trials in Pittsburgh
We’re tracking 70 recruiting neoplasms studies with a site in or near Pittsburgh — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Pittsburgh
- NCT03391778Enrolling by invitationPhase 1
Long-term follow-up for cell therapy participants
This study checks how people do over time after receiving an “adoptive cell therapy” treatment. It helps researchers understand long-term safety and outcomes after prior participation in related studies.
Pittsburgh, PennsylvaniaAges Any age - NCT03435796RecruitingPhase 2/Phase 3
Follow-up for people treated with gene-modified T cells
This study is a long-term check-in for people who previously received gene-modified T-cell infusions in a related Celgene/Juno/BMS trial. It helps researchers track safety and long-term effects over time.
Pittsburgh, PennsylvaniaAges Any age - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT01042379RecruitingPhase 2
Adaptive drug trial for newly diagnosed breast cancer
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial tests an experimental drug called NKT3964 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Pittsburgh, PennsylvaniaAges 19 years+ - NCT02402244Recruiting
Caring registry study for children and young people with cancer
This study keeps a careful record of children, teens, and young adults with cancer (and some related growths) and may follow them over time. It helps researchers better track outcomes and future contact so care can improve.
Pittsburgh, PennsylvaniaAges Up to 25 years - NCT02984761Recruiting
Surgery vs focused radiation for early lung cancer
This trial compares two ways to treat early-stage lung cancer: surgery or a precise type of radiation called stereotactic radiotherapy. It aims to find out which approach works best for people whose cancer is small and has not spread.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05614739RecruitingPhase 1
Study of vepugratinib for cancers with FGFR3 gene changes
This study tests a new pill, vepugratinib, for people whose cancer has a specific change in a gene called FGFR3. The drug targets this gene change to try to slow or shrink the cancer, and may be an option if standard treatments have not worked.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT04075305Recruiting
Study measuring radiation treatment outcomes with an MR-Linac
This study follows what happens when radiation treatment is guided using an MR-Linac (a special machine that combines MRI imaging with radiation). It may help improve how radiation therapy is planned and assessed, especially for people who can safely have MRI scans.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06919965RecruitingPhase 3
TAR-210 vs. standard bladder chemo for high-risk bladder cancer
This trial compares a new drug called TAR-210, given directly into the bladder, to standard chemotherapy for people with a specific type of high-risk bladder cancer that has not invaded muscle. It tests if TAR-210 can be more effective with fewer side effects.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06906341RecruitingPhase 2
Relacorilant combo for gynecologic cancers
This trial tests a drug called relacorilant combined with different treatments for ovarian, fallopian tube, primary peritoneal, or endometrial cancers. It may help patients whose cancer has stopped responding to standard therapies.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06662786RecruitingPhase 3
Amivantamab plus chemo vs. standard chemo for left-sided colorectal cancer
This trial compares a new combination (amivantamab plus chemotherapy) with the standard treatment (cetuximab plus chemotherapy) as the first therapy for people with left-sided colorectal cancer that has spread. The goal is to see which approach works better when the tumor has no mutations in the KRAS, NRAS, or BRAF genes.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT04429542RecruitingPhase 1
Test of an EGFR-targeting drug for advanced solid cancers
This Phase 1 study tests the safety of BCA101 (an EGFR-targeting treatment) alone or combined with pembrolizumab. It may help people with certain EGFR-driven advanced cancers, depending on the tumor type, prior treatments, and required biopsy testing.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06105749Recruiting
Biennial contrast-enhanced mammogram for breast cancer survivors
This study tests whether getting a contrast-enhanced mammogram (CEM) every two years is effective for detecting breast cancer in women who have had breast cancer before. If you qualify, you will receive CEM instead of a standard mammogram to see if it helps find cancer earlier.
Pittsburgh, PennsylvaniaAges 30–79 - NCT06119581RecruitingPhase 3
Oloromosib with Immunotherapy as First Treatment for KRAS G12C Lung Cancer
This trial tests a new targeted pill (olomorasib) combined with immunotherapy (pembrolizumab) and possibly chemotherapy for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and has not been treated before.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06126276RecruitingPhase 2
Testing neratinib with or without palbociclib for HER2+ solid tumors
This trial tests two targeted drugs—neratinib alone or with palbociclib—for people with HER2-positive solid tumors (other than breast cancer) that have returned or not gone away. The goal is to see if blocking HER2 and CDK4/6 can shrink or slow the tumor.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT02285582Recruiting
Rare blood disorder registry for histiocytic conditions
This study is a registry that collects information about people diagnosed with rare histiocytic disorders. It helps doctors better understand these conditions over time and may improve future care.
Pittsburgh, PennsylvaniaAges Any age - NCT07621614RecruitingPhase 2
Safe Surgery Guidance for Childhood Melanoma Using Genetics
This study helps doctors decide the safest surgical approach for melanoma and similar skin tumors in children and young adults by using pathology reports and genetic information. The goal is to avoid unnecessary surgery while ensuring the best outcomes.
Pittsburgh, PennsylvaniaAges Up to 25 years - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Pittsburgh, PennsylvaniaAges 1–30 - NCT06926868RecruitingPhase 2/Phase 3
Study of a new drug versus chemotherapy for advanced triple-negative breast cancer
This trial tests a new investigational drug called izalontamab brengitecan against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. The goal is to see if the new drug works better at shrinking or slowing the cancer.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT03970096RecruitingPhase 2
Reduce graft-versus-host disease after stem cell transplant
This Phase 2 study tests ways to lower the risk of graft-versus-host disease (GVHD), a serious complication after an allogeneic stem cell transplant from a matched donor. It is for people with acute leukemia or MDS who are going to receive intensive conditioning therapy, aiming to improve safety while keeping the transplant effective.
Pittsburgh, PennsylvaniaAges 1–60 - NCT06256588RecruitingPhase 3
Dostarlimab vs placebo after chemoradiation for head and neck cancer
This study tests whether the immunotherapy drug dostarlimab, given after standard chemoradiation, can keep advanced head and neck cancer from coming back. It is for people who have not had surgery and whose tumors are PD-L1 positive.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07001592RecruitingPhase 1
Injection of a modified virus for advanced GI and peritoneal cancers
This trial tests a modified virus injected directly into tumors to treat metastatic gastrointestinal and peritoneal cancers. It aims to see if this approach can shrink tumors or slow their growth.
Pittsburgh, PennsylvaniaAges 18–69 - NCT03759717Recruiting
Study of skull base tumors using tumor tissue
This study aims to learn more about skull base tumors by examining tumor tissue from surgery. It may help doctors better understand these tumors and improve future care.
Pittsburgh, PennsylvaniaAges Any age
Hear when a new Neoplasms trial opens near Pittsburgh, PA
We’ll email you when one opens near Pittsburgh, PA — at most once a week, no account needed, unsubscribe anytime.
Neoplasms trials in other cities
Where these studies are running near Pittsburgh
Institutions with a site for the recruiting neoplasms studies listed above.
- UPMC Hillman Cancer Center · 6 studies
- Allegheny Health Network · 3 studies
- University of Pittsburgh Medical Center · 3 studies
- UPMC Children's Hospital of Pittsburgh · 3 studies
- UPMC Cancer Centers - Arnold Palmer Pavilion · 2 studies
- UPMC Hillman Cancer Center - Monroeville · 2 studies
- UPMC Magee-Womens Hospital · 2 studies
- UPMC Passavant Hospital · 2 studies
What taking part in a neoplasms study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting neoplasms studies in Pennsylvania.
Common questions
- Are there neoplasms clinical trials near Pittsburgh?
- Yes. We're currently tracking 70 recruiting neoplasms studies with a site near Pittsburgh, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a neoplasms study near Pittsburgh?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pittsburgh to take part?
- Not necessarily. These studies have a site near Pittsburgh, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a neoplasms trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New neoplasms studies open near Pittsburgh regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.